Preferences of patients and clinicians for treatment of Graves' disease: a discrete choice experiment
- PMID: 33780350
- DOI: 10.1530/EJE-20-1490
Preferences of patients and clinicians for treatment of Graves' disease: a discrete choice experiment
Abstract
Objective: Treatment options for Graves' disease (GD) consist of antithyroid drugs (ATD), radioactive iodine (RAI) and total thyroidectomy (TT). Guidelines recommend to discuss these options with patients, taking into account patients' preferences. This study aims to evaluate and compare patients' and clinicians' preferences and the trade-offs made in choosing treatment.
Design and methods: A discrete choice experiment (DCE) was performed with GD patients with a first diagnosis or recurrence in the previous year, and with clinicians. Participants were offered hypothetical treatment options which differed in type of treatment, rates of remission, severe side effects, permanent voice changes and hypocalcemia. Preference heterogeneity was assessed by latent-class analysis.
Results: In this study, 286 (82%) patients and 61 (18%) clinicians participated in the DCE. All treatment characteristics had a significant effect on treatment choice (P < 0.05). Remission rate was the most important determinant and explained 37 and 35% of choices in patients and clinicians, respectively. Both patients and clinicians preferred ATD over surgery and RAI. A strong negative preference toward RAI treatment was observed in a subclass of patients, whereas clinicians preferred RAI over surgery.
Conclusion: For both patients and clinicians, remission rate was the most important determinant of treatment choice and ATD was the most preferred treatment option. Patients had a negative preference toward RAI compared to alternatives, whereas clinicians preferred RAI over surgery. Clinicians should be aware that their personal attitude toward RAI differs from that of their patients. This study on patients' and clinicians' preferences can support shared decision making and thereby improve clinical treatment.
Similar articles
-
Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study.Thyroid. 2020 Mar;30(3):357-364. doi: 10.1089/thy.2019.0132. Epub 2020 Feb 26. Thyroid. 2020. PMID: 31973681
-
Outcomes of Graves' Disease Patients Following Antithyroid Drugs, Radioactive Iodine, or Thyroidectomy as the First-line Treatment.Ann Surg. 2021 Jun 1;273(6):1197-1206. doi: 10.1097/SLA.0000000000004828. Ann Surg. 2021. PMID: 33914484
-
Definitive treatment of Graves' disease in children and adolescents.Endokrynol Pol. 2021;72(6):661-665. doi: 10.5603/EP.a2021.0092. Epub 2021 Dec 2. Endokrynol Pol. 2021. PMID: 34855196
-
Comparing antithyroid drugs vs. radioactive iodine in paediatric Graves' disease: literature review.Thyroid Res. 2025 May 14;18(1):27. doi: 10.1186/s13044-025-00238-7. Thyroid Res. 2025. PMID: 40369601 Free PMC article. Review.
-
Pediatric Graves' disease: controversies in management.Horm Res Paediatr. 2010;74(5):305-11. doi: 10.1159/000320028. Epub 2010 Oct 2. Horm Res Paediatr. 2010. PMID: 20924158 Review.
Cited by
-
Pet Owners' Preferences for Quality of Life Improvements and Costs Related to Innovative Therapies in Feline Pain Associated with Osteoarthritis-A Quantitative Survey.Animals (Basel). 2024 Aug 8;14(16):2308. doi: 10.3390/ani14162308. Animals (Basel). 2024. PMID: 39199842 Free PMC article.
-
Risk of recurrence at the time of withdrawal of short- or long-term methimazole therapy in patients with Graves' hyperthyroidism: a randomized trial and a risk-scoring model.Endocrine. 2024 May;84(2):577-588. doi: 10.1007/s12020-023-03656-5. Epub 2024 Jan 2. Endocrine. 2024. PMID: 38165576 Clinical Trial.
-
Methimazole Desensitization in a Patient Experiencing a Thionamide-induced Hypersensitivity Reaction.JCEM Case Rep. 2024 May 27;2(6):luae066. doi: 10.1210/jcemcr/luae066. eCollection 2024 Jun. JCEM Case Rep. 2024. PMID: 38803510 Free PMC article.
-
Dog Owners' Perceptions of the Convenience and Value of Chewable Oclacitinib: Quantitative Survey Data from an International Survey.Animals (Basel). 2024 Mar 19;14(6):952. doi: 10.3390/ani14060952. Animals (Basel). 2024. PMID: 38540050 Free PMC article.
-
Enhanced predictive validity of integrative models for refractory hyperthyroidism considering baseline and early therapy characteristics: a prospective cohort study.J Transl Med. 2024 Mar 29;22(1):318. doi: 10.1186/s12967-024-05129-3. J Transl Med. 2024. PMID: 38553734 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials